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Abstract: The tumor biology targeted therapies have improved outcomes in colorectal cancer 
(CRC). The epidermal growth factor receptor (EGFR) inhibitors represent one of these 
successful strategies. EGFR is frequently overexpressed in CRCs and associated with a malig-
nant phenotype. Two EGFR inhibitors have shown efficacy in metastatic CRC, cetuximab 
and panitumumab. Cetuximab is a human–mouse chimeric monoclonal antibody that binds to 
the extracellular domain of the EGF-receptor. Similarly, panitumumab is a fully humanized 
monoclonal IgG2 antibody, directed against EGFR. Being fully humanized, panitumumab does 
not contain mouse protein reducing the risk of hypersensitivity. In a pivotal clinical trial, pani-
tumumab was well tolerated and effective, demonstrating an objective response rate of 10% vs 
best supportive care (ORR = 0%; P  0.0001). Panitumumab was approved for the treatment of 
mCRC by the FDA in 2006. Studies combining panitumumab with cytotoxic chemotherapy and 
other targeted therapies have been completed while others are ongoing to further evaluate the 
clinical utility of this agent. Recently it has been demonstrated that mutations in KRAS predict 
the efficacy of panitumumab and cetuximab, limiting their use to CRC patients with wild-type 
KRAS, and moving the clinical field towards personalized cancer care.
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Introduction
World-wide, colorectal cancer is the third most common cancer in both men and women. 
In 2008, it is estimated that 148,810 cases of colorectal cancer will be diagnosed and 
49,960 people will die from this disease.1 Despite the prevalence of this disease, the 
overall incidence and death rates have declined over the last 20 years, suggesting 
improvements in early detection and treatments. Unfortunately, approximately 20% 
of patients will have metastatic disease at the time of presentation. Chemotherapeutic 
agents that have been US Food and Drug Administration (FDA) approved for the use 
in metastatic colorectal cancer (mCRC) include 5-fluorouracil (5-FU), capecitabine, 
irinotecan and oxaliplatin. In recent clinical trials, the median overall survival for 
patients treated with irinotecan and oxaliplatin-based regimens approaches 20 months, 
an improvement in comparison to the 12 month median survival prior to the approval 
of these agents.2,3
As we learn more about the biology of cancer and its pathways, potential targets for 
therapy have been identified. These novel biologic agents are well poised to potentially 
advance the progress of the treatment of mCRC. Bevacizumab, an anti-angiogenic agent, 
is an example of a targeted agent improving outcomes in mCRC. The addition of bevaci-
zumab to a combination chemotherapy regimen of irinotecan, 5-FU and leucovorin (IFL) OncoTargets and Therapy 2009:2 162
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increased the median duration of survival from 15.6 months 
(IFL) to 20.3 months (bevacizumab plus IFL; P  0.001).4
The epidermal growth factor receptor (EGFR) has been 
shown to be frequently overexpressed in CRC5,6 and has been 
associated with a malignant phenotype.6–9 Multiple clinical 
trials have been performed and are currently ongoing to 
evaluate EGFR-targeted agents in CRC. Thus far, two EGFR 
inhibitors have shown efficacy in mCRC, namely cetuximab 
(Erbitux®; ImClone Systems, Brachburg, NJ, USA) and 
panitumumab (Vectibix®; Amgen, Thousand Oaks, CA, 
USA). Cetuximab, a human–mouse chimeric monoclonal 
antibody that binds specifically to the extracellular domain of 
the EGF-receptor results in inhibition of cellular growth, and 
angiogenesis and promotes apoptosis. Significant improve-
ment in overall response rates were demonstrated in patients 
with colorectal cancer, refractory to irinotecan, who received 
cetuximab in combination with irinotecan (overall response 
rate [ORR] 22.9%) vs cetuximab alone (ORR 10.8%).10 There 
was a trend in improved overall survival for the cetuximab 
in combination with irinotecan arm vs the cetuximab alone 
arm (8.6 months vs 6.9 months, P = 0.48). The results of this 
study led to the approval of cetuximab for the treatment of 
patients with mCRC.
Panitumumab is a fully humanized monoclonal anti-
body to EGFR that has shown encouraging activity and 
tolerability in heavily pretreated patients with MCRC. It 
selectively targets the extracellular domain of the EGFR. 
It was Food and Drug Administration (FDA) approved in 
September 2006 and is currently indicated for the treatment 
of mCRC in EGFR-expressing tumors that have progressed 
following treatment with fluoropyrimidine-, oxaliplatin-, 
and irinotecan-containing chemotherapy regimens. There 
are also ongoing trials in first- and second-line settings. In 
this review, we will discuss the EGFR signaling pathway, 
focusing on panitumumab and its pharmacology and efficacy 
in colorectal cancer. We will also review the toxicities related 
to panitumumab as well as provide insight into potential 
biomarkers of response, including k-ras and BRAF.
EGFR signaling and its role 
in colorectal cancer
EGFR is a transmembrane tyrosine kinase, belonging to a 
family of human epidermal growth factor receptors (HER1). 
Other members within this family include HER2 (ERBB2), 
HER3 (ERBB3) and HER4 (ERBB4). All members within 
this family, with the exception of HER2, which has no 
apparent ligand, have an extracellular ligand-binding domain, a 
transmembrane lipophilic segment and an intracellular domain 
with tyrosine kinase activity. In response to ligand binding by 
the epidermal growth factor and transforming growth factor α 
(TGF-α), the EGFR homodimerizes and/or forms heterodimers 
with other members of the ERBB family (especially HER2). 
This then leads to the activation of EGFR tyrosine kinases 
through phosphorylation. This phosphorylation results in the 
activation of several intracellular second-messenger signal 
transduction pathways, such as the Janus kinase-Signal trans-
ducer an activator of transcription signaling, the phosphati-
dylinositol-3-kinase and the protein-serine/threonine kinase 
Akt signal, and the Ras-Raf-MAP-kinase signal, which further 
activates the mitogen-activated phosphorylation protein 
kinases. Ultimately, the signaling of the pathways leads to 
increased cell proliferation, division, survival, invasion, adhe-
sion and DNA repair in malignant and nonmalignant cells. If 
these pathways are dysregulated, such as in the case of EGFR 
overexpression, alterations in cellular growth, survival, angio-
genesis and metastases may occur.11–18
The proposed development of colorectal cancer evolves 
from the progressive accumulation of genetic and epigenetic 
alterations resulting in the transformation of normal colonic 
mucosa to invasive adenocarcinoma.19 EGFR has been impli-
cated in the initiation of colorectal tumors and has also been 
noted to be frequently overexpressed in CRC.5,20 The prog-
nostic significance of EGFR in CRC remains unclear.6,20
Panitumumab pharmacology 
and pharmacokinetics
Panitumumab (ABX-EGF, E.7.6.3, Vectibix®), is a high-
affinity, fully humanized monoclonal IgG2 antibody, 
directed against EGFR, generated in XenoMouse® (Abjenix, 
Fremont, CA; transgenic mouse capable of producing human 
antibodies). It is produced by immunizing a XenoMouse 
strain of mice with human cervical epidermal carcinoma cell 
line A431, a cell line known for its abundance of EGFR on the 
cell surface.21,22 Unlike chimeric antibodies, fully humanized 
monoclonal antibodies do not contain any amount of foreign 
elements (ie, mouse protein) and thus do not generate human 
antimouse antibodies. This reduces this risk of hypersensi-
tivity reactions and thus, represents a theoretical clinical 
advantage over previously developed chimeric antibodies.
The mechanism of action of panitumumab involves binding 
of panitumuab to the EGFR with inhibition of ligand binding 
of EGFR. It is rapidly internalized but not degraded internally. 
The binding of panitumumab to EGFR results in downregula-
tion of cell-surface EGFR by internalization of the receptor, 
interruption of the intracellular signaling EGFR resulting 
in apoptosis and initiation of cell-cycle arrest, inhibition of OncoTargets and Therapy 2009:2 163
Panitumumab in colorectal cancer treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
angiogenesis and possible inhibition of differentiation of the 
tumor cells. With panitumumab being an IgG2 isotype, it is 
unlikely to produce an immunologic-mediated response. Thus, 
antibody-dependant cellular cytotoxicity (ADCC) is not impli-
cated in panitumumab’s mechanism of action.23,24
The recommended dose of panitumumab is 6 mg/kg 
given over 60 minutes as an intravenous infusion once every 
2 weeks (package insert Vectibix: Thousand Oaks, CA: 
Amgen Inc, Sept 2006). According to the manufacturer, 
available pharmacokinetic data do not indicate that sex, age, 
ethnicity, mild-to-moderate renal or hepatic dysfunction or 
EGFR membrane-staining intensity in tumor cells affect the 
pharmacokinetic properties of panitumumab. Use of the drug 
has not been evaluated in pediatric and pregnant patients. 
There have also not been any formal pharmacokinetic studies 
performed in patients with hepatic and/or renal dysfunction.
Phase I studies
Panitumumab was initially evaluated in a multicenter, 
open-label, dose-escalating phase I trial, where 43 patients 
with various solid tumor types; renal (n = 10), prostate 
(n = 13), non-small-cell lung cancer (n = 7), pancreatic (n = 
3), esophageal (n = 3) and CRC (n = 7), received 4 intra-
venous infusions of panitumumab once weekly for up to 1 
hour, at doses ranging from 0.01 mg/kg to 2.5 mg/kg. In all 
the patients receiving the 2.0 to 2.5 mg/kg dose, a transient 
dose-dependent skin rash was noted. No allergic reactions, 
infusion reactions or serious adverse events were noted and 
no human anti-human antibodies (HAHA) were found.25 
Those patients with evidence of response or stable disease 
were eligible to continue to receive treatment every other 
week for 6 additional months or until disease progression. 
Biologic activity was noted in patients even at the lowest 
doses. One patient with esophageal cancer treated with the 
lowest dose had stable disease (SD) for 7 months. A partial 
response (PR) of 10 months duration was noted in one patient 
with colorectal cancer treated with the 2.5 mg/kg dose.
An additional 50 patients were treated on the above study 
and the updated results were presented by Weiner et al at the 
ASCO 2005 meeting and has been subsequently published.26 
Sequential cohorts were enrolled to receive four infusions 
of panitumumab as a single-agent. There were different 
dose levels ranging from 0.01 mg/kg to 5.0 mg/kg once 
per week, 6.0 mg/kg every 2 weeks and 9.0 mg/kg every 
3 weeks. A total of 96 patients were enrolled and treated 
(CRC, n = 39, lung, n = 14, pancreatic, n = 21, renal, n = 15, 
esophageal, n = 3 and anal cancer, n = 1). 10% of the patients 
experienced Grade 3 or 4 toxicities, with Grade 3 skin rash 
being the most common adverse event noted (7%). Dose 
escalation to 9.0 mg/kg every 3 weeks was achieved and no 
maximal tolerated dose was reached. Pharmacokinetics were 
consistent and predictable over the range of dosing, with low 
intra-patient and inter-patient variablility. The minimal serum 
panitumumab concentrations (Ctrough) were similar among 
all the dose levels, with steady-state reached after approxi-
mately 6 weeks for all dosing schedules. Thus, even though 
the maximum tolerated dose was not reached, the authors 
decided that increasing the dose beyond those tested, would 
unlikely result in increased panitumumab activity. Five of 
the 39 CRC patients (13%) achieved a partial response (PR) 
with 9 of 39 CRC patients (23%) had stable disease.
Rowinsky et al27 performed a phase I study of panitu-
mumab in previously treated patients with metastatic renal 
cell carcinoma. The primary objectives of the study were to 
evaluate toxicity, immunogenicity, pharmacokinetics as well 
as pharmacodynamics. A total of 88 patients were enrolled 
and treated with panitumumab. They were treated with pani-
tumumab doses of 1.0, 1.5, 2.0 or 2.5 mg/kg weekly with no 
loading dose. Major responses were seen in three patients 
and two patients had minor responses. Forty four patients 
had stable disease (50%) at their first assessment at 8 weeks. 
The median progression-free survival was 100 days [95% 
confidence interval (CI), 58 to 140 days]. The main toxicity 
noted was an acneiform rash which was dose dependant, 
with 68, 95, 87 and 100% of patients who received at least 
3 doses of panitumumab at 1.0, 1.5, 2.0, and 2.5 mg/kg/week 
respectively. The rash reached maximal intensity at weeks 3 
and 5, and then continued to dissipate despite ongoing treat-
ment. Other frequent toxicities noted were asthenia, unspeci-
fied pain and back pain.
Phase II studies
Panitumumab as single-agent in treatment 
of metastatic colorectal cancer
A number of phase II studies have confirmed the clinical 
activity of panitumumab as well as the safety as reported in 
earlier clinical trials. In the pivotal phase II trial by Malik et al 
148 heavily pretreated patients with metastatic CRC were 
treated with panitumumab administered at 2.5 mg/kg/week 
over 1 hour with no loading dose or premedications.28 Patients 
were enrolled into two cohorts, depending on levels of EGFR 
protein expression (as determined by immunohistochemistry). 
All the enrolled patients had received prior treatment with 
fluoropyrimidines, 96% had received irinotecan therapy and 
49% had received prior oxaliplatin therapy. Patients were OncoTargets and Therapy 2009:2 164
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allowed to continue on panitumumab as long as it was 
tolerated and there was clinical benefit.
The most common toxicities noted were rash and fatigue. 
The rash typically appeared within 1 to 3 weeks of initiat-
ing therapy and persisted, without worsening throughout 
therapy. Only 4 patients discontinued therapy due to rash. It 
was classically described as a maculopapular acneiform rash, 
appearing on the face and trunk. Only 1 patient had a grade 3 
infusion reaction and no HAHA antibodies were detected in 
the 107 patients tested.
Nine per cent (13) patients were found to have responded 
after 8 weeks of therapy, with 29% of patients with SD. The 
median duration of response was 5.2 months and median OS 
of 9.4 months. No significant difference was noted when the 
results were analyzed according to the two cohorts based on 
EGFR protein expression.
As with other EGFR inhibitors, there was a trend in the 
correlation between the severity of the rash and response. At 
least 62% of the patients who developed a rash of grade 2 or 
more had either PR or SD.
Another phase II trial was undertaken to evaluate the effi-
cacy of panitumumab in patients with mCRC, having received 
more than 2 lines of previous therapy and whose tumors 
expressed EGFR in 10% or more of the cells. Panitumumab 
was given at 6 mg/kg every 2 weeks until disease progres-
sion. By 16 weeks, 8% of patients had a PR, with 21% 
having SD. The most common toxicities noted were rash 
(96%), nail (30%) and eye (8%) reactions, diarrhea (27%) 
and hypomagnesemia (12%). One patient developed a grade 
3 hypersensitivity reaction but continued on with therapy 
without further reactions. No HAHA were detected.29
Patients with metastatic CRC with low (1% to 9%) or no 
(1%) expression of EGFR were evaluated in another phase II 
trial.30 In the 89 patients available for efficacy analysis, partial 
responses and tumor control rates ranged from 7% to 9% 
and 37% to 42% respectively. This is comparable with the 
responses seen in patients with EGFR-expressing tumors. 
Among the 118 patients evaluable for toxicity analysis, 72% 
developed rash, 69% with erythema, pruritus in 65% and 
hypomagnesemia in 53%. Three patients developed infusion 
reactions, with only one being a grade 3 reaction.
Panitumumab in combination 
with cytotoxic chemotherapy  
or biologic agents
With other EGFR inhibitors, there has been a suggestion 
of synergy or an additive effect with chemotherapy.10 
Preclinical studies have also demonstrated that panitumumab 
may also have an additive antitumor effect when used in 
combination with cytotoxic chemotherapy.
Panitumumab (given at 2.5 mg/kg/week) in combination 
with IFL (Saltz regimen: irinotecan 125 mg/m2, leucovorin 
20 mg/m2 and 5-FU 500 mg/m2 on days 1, 8, 15 and 22) 
was evaluated in patients with metastatic colorectal cancer 
as first-line therapy.31,32 The primary objectives of the study 
were to evaluate both safety and efficacy. All patients were 
required to have EGFR expression of 2+ or 3+ in 10% of 
tumor cells by immunohistochemistry. The first 19 patients 
received panitumumab in combination with IFL weekly 
for 4 weeks of each 6-week treatment cycle. The protocol 
was amended to include another regimen (based on data 
from the first few patients and changing practice from 
bolus to infusional 5-FU), FOLFIRI (irinotecan 180 mg/m2, 
leucovorin 400 mg/m2 and 5-FU as a 400 mg/m2 bolus 
followed by 2.4 to 3 g/m2 over 46 hours).
Diarrhea was the most common noncutaneous toxicity 
noted in the 19 patients that received panitumumab and IFL. 
Skin toxicity was found in 100% of patients. Sixteen per cent 
experienced a grade 3 skin reaction with no grade 4 events. 
Forty-seven per cent experienced grade 3 diarrhea with only 
1 patient having grade 4 diarrhea.
The overall response rate was 47% with an additional 
5 patients (26%) with stable disease. The disease control rate 
(DCR = OR + SD) was noted to be 74%. The median PFS 
and OS were 5.6 months and 17 months respectively.
Twenty-four patients were enrolled into the expanded 
portion of the study, evaluating panitumumab in combination 
with FOLFIRI. As previously noted in earlier trial, FOLFIRI 
was better tolerated with fewer patients experiencing grade 
3 and grade 4 diarrhea (25% and 0%, respectively). 100% 
of the patients experienced skin-related toxicity with grade 
3 reactions in 17% and no grade 4 reactions.
The response rates were very similar to the earlier 
portion of the study, with the DCR of 79% and median PFS 
of 10.9 months. OS data have not been reported yet. This 
has ultimately led to a randomized trial of FOLFIRI with or 
without panitumumab, which is currently underway.
Phase III studies
Van Cutsem et al’s multicenter, randomized phase III 
registration trial for panitumumab included a population of 
heavily pretreated patients with metastatic CRC.33 A total of 
463 patients with 1% EGFR-expressing tumors, measur-
able disease with radiological evidence of disease progression 
during or within 6 months of their most recent chemotherapy OncoTargets and Therapy 2009:2 165
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were enrolled. They were randomized to receive either 
6 mg/kg of panitumumab every 2 weeks plus best supportive 
care (n = 231) or best supportive care (BSC) alone (n = 232). 
Assessment of treatment response was performed at 8 week 
intervals and patients continued on treatment until disease 
progression or intolerable toxicity was noted. The primary 
endpoint was progression-free survival. Secondary endpoints 
included objective response, overall survival and safety. 
Patients randomized to BSC alone were allowed to crossover 
to receive BSC with panitumumab if they were noted to have 
disease progression. Panitumumab was found to significantly 
prolong PFS (P  0.0001). At 8 weeks, 49% and 30% of 
patients in the panitumumab and BSC groups, respectively, 
has no evidence of progression.
Objective response rates also favored panitumumab 
plus BSC arm (10%) over BSC alone (0%; p  0.0001). The 
median time to response was 7.9 weeks and median duration 
of response was 17.0 weeks. Stable disease was noted in 
64 (28%) and 24 (10%) of patients in the panitumumab and 
the BSC arms, respectively (results summarized in Table 1). 
No difference in overall survival was noted, however this was 
most likely due to the large number of patients in the BSC 
arm that were allowed to crossover to receive panitumumab 
on disease progression. In a subgroup analysis, there was a 
correlation with skin reactions (grade 2 and 3 skin toxicity) 
and prolonged PFS and OS. Other common toxicities 
included hypomagnesemia, paronychia, fatigue, abdominal 
pain, nausea and diarrhea. The most severe toxicities included 
pulmonary fibrosis, severe dermatologic toxicity complicated 
by sepsis and death and infusion reactions.
Thus, panitumumab in combination with BSC was found 
to have antitumor activity in patients who had received 
multiple previous chemotherapy agents. Results are com-
parable to those reported with single-agent cetuximab in the 
same setting.10 Although response rates are only 10%, more 
than a third of the patients had significant clinical benefit 
with minimal toxicity. The trial design also allowed for 
crossover to include addition of panitumumab to BSC. This 
likely explains the lack of statistical difference in overall 
survival between the two arms. Thus, panitumumab was 
granted FDA approval in September 2006 for the treatment of 
patients with EGFR-expressing, metastatic CRC with disease 
progression on or following fluoropyrimidine-, oxaliplatin-, 
and irinotecan-containing chemotherapy regimens.
More recently, the role of panitumumab was investigated 
in combination with both cytotoxic chemotherapy and bio-
logic agent, bevacizumab. The PACCE trial (Panitumumab 
Advanced Colorectal Cancer Evaluation) was a randomized, 
open-label, multicenter phase IIIB trial originally intended 
to assess the efficacy and safety of bevacizumab plus 
FOLFOX4 or FOLFIRI (doses and schedules determined by 
investigators), with or without panitumumab, in the first-line 
setting.34 In March 2007, a pre-planned interim analysis of 
the first 231 events revealed that there was a statistically 
significant difference in progression-free survival (PFS) 
in favor of the control arm (without panitumumab). PFS 
was significantly worse in the panitumumab arm of the 
oxaliplatin-based chemotherapy (HR, 1.44; 95% CI, 1.13 to 
1.85; P = 0.004). Median PFS time was 8.8 months (95% CI, 
8.3 to 9.5 months) for panitumumab and 10.5 months (95% 
CI, 9.4 to 12.0 months) for the control arm.
For the irinotecan-based chemotherapy cohort, median 
PFS was 10.1 months for panitumumab and 11.9 months for 
the control arm (HR, 1.57; 95% CI, 0.71 to 3.46). Toxici-
ties, notably diarrhea, infections and pulmonary embolism 
were also increased in the panitumumab arm. Thus, Amgen 
decided to discontinue the panitumumab treatment arm in the 
PACCE trial.34,35 The exact mechanism is currently unknown 
but a few hypotheses suggested by the authors included phar-
macokinetic interactions as well as increase in toxicity due to 
dual-pathway inhibition in combination with chemotherapy. 
Increased toxicity may have lead to more dose reductions, 
Table 1 Summary of phase iii registration trial results comparing best supportive care with panitumumab monotherapy in patients with 
previously treated metastatic colorectal cancer, having failed irinotecan- and oxaliplatin-based therapy
Panitumumab arm 
(n = 232)
Best supportive care 
(n = 231)
PFS at 24 weeks (%) 18% 5%
PFS at 32 weeks (%) 10% 4%
rr (%) 8% 0%
Stable disease (%) 28% 10%
Disease control rate (%) 36% 10%
Median duration of response (weeks) 17 weeks N/A
Abbreviations: PFS, progression-free survival; rr, response rate.OncoTargets and Therapy 2009:2 166
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treatment delays, decreases in dose intensity resulting in the 
inferior results in the panitumumab arms.
A potential pharmacodynamic interaction induced by 
EGFR inhibition may have also led to a blunting of the thera-
peutic effects of bevacizumab and/or chemotherapy.34
Ongoing studies
Currently, a number of phase I–III trials are evaluating 
panitumumab in combination with cytotoxic chemotherapy 
and/or biologic agents. For current trials, refer to Table 2.
Toxicity profile
The toxicity profile of panitumumab has been found to be 
both favorable as well as highly predictable when evaluated 
with pooled data in two safety analyses.36,37 Most common 
toxicities included acneiform rash (all grades 53% to 4%; 
Grade 3 and 4, 2% to 6%), pruritus (all grades 52% to 53%), 
erythema (all grades 52% to 54%), paronychia (all grades 
20%), fatigue (all grades 33% to 34%, grade 3 and 4, 6%), 
nausea (all grades 29% to 30%, grade 3 and 4, 2%), diar-
rhea (all grades 26% to 27%, grade 3 and 4, 3%), abdominal 
pain (all grades 21%, grade 3 and 4, 5%), hypomagnesemia 
with clinical symptoms (all grades 5% to 6%, grade 3 
and 4, 1% to 2%), hypomagenesemia without clinical symp-
toms (all grades 38% to 44%, grade 3 and 4, 5% to 6%). 
The general incidence of treatment-related adverse events 
experienced with panitumumab included 93% to 94% any 
grade, 18% grade 3 and 1% grade 4. No deaths have been 
reported that have been attributed to panitumumab. Three 
per cent to 4% of patients did discontinue therapy due to 
adverse toxicities.
Biomarkers of response
Even though EGFR inhibitors do demonstrate antitumor 
activity in CRC and are well tolerated, there are still a 
significant portion of patients who do not respond to these 
therapies or have intolerable toxicities. With the ongoing 
interest in personalizing cancer care, the shift has been to 
identify markers of response as well as toxicity.
Skin toxicity with grade 3 or grade 4 rash has been 
demonstrated to be a clinical marker of response. The under-
lying rationale for this has yet to be determined. It does not 
appear to correlate with EGFR expression in tumor cells 
(evaluated by immunohistochemistry). In a subset analysis 
of Van Cutsem et al’s phase III trial of panitumumab vs best 
supportive care, correlation was noted with severity of rash 
and longer OS and PFS as well as improved quality-of-life 
measures.38,39 There has also been some suggestion that skin 
toxicity may be a proposed surrogate marker for response to 
cetuximab therapy10,40 and that dose escalation of cetuximab 
aimed at increasing severity of skin rash may indeed increase 
response rate. However, the overall effect was modest with 
no statistically significant impact on disease control rates.41
Expression of EGFR itself has previously been 
demonstrated to have no impact on response or clinical 
benefit.10,40,42–45 Other markers of response to anti-EGFR 
therapy have been investigated including EGFR gene 
amplification and/or expression, EGFR mutations as well 
as KRAS mutations. Most of the studies were performed in 
non-small cell lung cancer; however, KRAS mutations have 
been reported to be relatively common in sporadic CRC (30% 
to 50% incidence).46–51 Several previous studies have identi-
fied the presence of mutated KRAS in lung and CRC tumors, 
correlating with poorer prognosis50–54 and is also associated 
with lack of response to anti-EGFR therapy.48,49,55–58 Up to 
90% of activating mutations of the RAS gene are detected 
on codons 12 and 13, but less frequently also in codon 61 
and 63. In CRC, majority of the mutations (70%) occur in 
codon 12, with 30% occurring in codon 13.59 Mutations of 
the KRAS gene may activate downstream signal transduction 
leading to resistance to upstream inhibition of the EGFR by 
monoclonal antibodies.
Amado et al evaluated KRAS mutational status on patients 
treated in a randomized, trial evaluating panitumumab vs 
best supportive care.60 KRAS mutational status was obtained 
on 427 (92%) of 463 patients (208 panitumumab arm, 219 
BSC). KRAS mutations were detected by polymerase chain 
reaction on DNA from tumor sections. KRAS mutations were 
identified in 43% of patients. The results of the analysis 
identified that the treatment effect on PFS on the wild-type 
(WT) KRAS group (HR, 0.45; 95% CI, 0.34 to 0.59) was 
significantly greater (P  0.0001) than in the mutant group 
(HR, 0.99: 95% CI, 0.73 to 1.36). The median PFS in the 
WT KRAS group was 12.3 weeks for panitumumab and 7.3 
weeks for BSC. Reponse rates to panitumumab were 17% 
and 0% for the WT and mutant groups respectively. WT 
KRAS patients also had longer overall survival (HR, 0.67; 
95% CI, 0.55 to 0.82). No significant differences in toxicity 
were noted between the two groups.
The same effect of KRAS mutational status has also 
been reported with cetuximab therapy.56,61 On the basis of 
these results, the European Union drug regulatory body, the 
European Medicines Agency, has approved panitumumab 
only for metastatic CRC patients whose tumors display only 
wild-type KRAS (Table 3). Currently, ASCO (American 
Society of Clinical Oncology) also recommends following OncoTargets and Therapy 2009:2 167
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these guidelines; however, the FDA has held off on making 
similar recommendations.
Santini et al recently reported high level of concordance 
in the KRAS status of metastatic lesions and primary tumors. 
In the metastatic setting, selecting therapy based on KRAS 
mutational status is becoming more widely accepted.62 
However, in the adjuvant setting, this is still under clinical 
investigation. If both the primary tumor and metastatic 
lesions share common characteristics such as KRAS muta-
tional status, we could propose selecting therapies in the 
adjuvant setting based on primary tumor characteristics, may 
ultimately improve outcomes and reduce toxicity and cost.
Although this has changed the face of EGFR-inhibitor 
therapy in CRC, only 30% to 50% of patient have KRAS 
mutations, thus leaving a large proportion of patients that do 
not respond to EGFR inhibitors despite having WT KRAS. 
Di Nicolantonia et al proposed that in the absence of KRAS 
mutations, resistance to EGFR inhibitors may be mediated by 
alterations in the RAS-RAF-MAPK pathway.63 BRAF muta-
tions occur in CRC in approximately 10%.64 BRAF mutations 
have been linked to microsatellite instability, a condition 
generally associated with better prognosis and resistance to 
standard chemotherapy.65 Thus, KRAS mutational status as 
well as microsatellite instability were evaluated in this trial. 
Patients were selected based on evidence that treatment out-
come could be attributed only to administration of cetuximab 
or panitumumab. All patients had 1% tumor cells express-
ing EGFR assessed by immunohistochemistry. Once again, 
KRAS was noted in approximately 30% of patients and was 
associated with resistance to cetuximab or panitumumab 
(P = 0.011). The BRAF V600E mutation was detected in 
11 of 79 patients with WT KRAS. None of the BRAF-mutated 
patients responded to treatment. None of the responders 
carried BRAF mutations (P = 0.029). BRAF mutations in 
patients led to a significantly shorter PFS (P = 0.011) and OS 
(P  0.0001) than patients with WT BRAF. Thus, patients 
whose tumors bear the BRAF V600E allele are unlikely 
to benefit from EGFR inhibitor therapy. This could be an 
additional tool for the selection of mCRC patients who may 
benefit from EGFR-targeted therapies.
The PI3K/Akt signaling pathway is involved in cell 
growth, resistance to apoptosis, invasion and migration. 
PTEN (the lipid phosphatase and tensin homolog) is a key 
tumor suppressor that normally regulates the activation of 
PI3K.66 The loss of PTEN and mutations in PI3K have been 
proposed to predict resistance to EGFR inhibitors, how-
ever, this is preliminary and no definite conclusions can be 
derived.64
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Conclusions
We are entering an exciting era in the treatment of colorectal 
cancer. Many advances have been made in the last few 
years, specifically the addition of targeted therapies in the 
treatment of mCRC. However, as we learn more about the 
agents as well as their mechanism of action, we are able to 
better target our treatment population. With the focus on 
developing personalized cancer care, the shift has been to 
tailor the treatment not only to the patient but also to tumor 
biology. It has become imperative to identify molecular and 
genetic mechanisms underlying responsiveness to mono-
clonal antibodies. This would allow us to select drugs for 
patients based on the tumor’s molecular signature, improving 
responses and outcomes, and avoiding unnecessary toxicities. 
By selecting drugs for responsive patients, we would also 
minimize the financial burden on the current healthcare 
system.64 In targeting the EGFR pathway, panitumumab has 
been shown to be well tolerated and effective in the treatment 
of metastatic colorectal cancer. However, panitumumab only 
be considered should in patients with wild-type KRAS.67
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